The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Level Of Market Value Growth Is Predicted For The Post-Operative Nausea And Vomiting Market From 2026 To 2030?
The market size for post-operative nausea and vomiting has experienced substantial growth in recent years. This market is anticipated to expand from $2.25 billion in 2025 to $2.41 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. The historical increase can be attributed to several factors, including rising surgical procedure volumes, a broader adoption of general anesthesia, the availability of serotonin antagonist drugs, the expansion of hospital surgical infrastructure, and improved post-operative care guidelines.
The market for post-operative nausea and vomiting is projected to experience substantial growth in the coming years, reaching $3.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.7%. This anticipated expansion throughout the forecast period stems from factors such as an increasing need for individualized anesthesia care, the greater implementation of preventive antiemetic strategies, the proliferation of ambulatory surgical facilities, a heightened emphasis on measures of patient satisfaction, and increased financial commitments to advancements in perioperative care. Key trends expected during this period involve the increasing integration of multimodal PONV management approaches, the heightened utilization of combined antiemetic treatments, a greater concentration on risk-stratified protocols, the broadening scope of non-pharmacological methods, and an amplified focus on improving patient comfort and recovery.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22109&type=smp
What Leading Drivers Are Supporting The Post-Operative Nausea And Vomiting Market Expansion?
An anticipated expansion in the post-operative nausea and vomiting market is linked to the growing volume of surgical procedures. These medical interventions involve the use of instruments to diagnose, treat, or excise compromised tissues, organs, or anomalies through incision or manipulation. The upward trend in surgical procedures is attributed to advances in medical technology, which have made operations safer, more effective, and less invasive, thereby increasing patient willingness and broad application. Effective management of post-operative nausea and vomiting improves surgical processes by boosting patient comfort, shortening recovery periods, reducing the likelihood of complications, facilitating easier post-operative care, and ultimately leading to better surgical outcomes. For example, in November 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that during the 2023–24 period, 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists, showing a 4.9% rise over 2022–23. Consequently, the increasing number of surgical procedures is fueling the expansion of the post-operative nausea and vomiting market. The expansion of healthcare infrastructure is projected to boost the post-operative nausea and vomiting market in the coming years. Healthcare infrastructure encompasses the physical sites, equipment, and organizational frameworks that facilitate the provision of healthcare services, such as hospitals, surgery centers, and medical technologies. This growth in infrastructure is mainly fueled by an increasing number of patients and a greater need for surgical procedures, as an aging population and higher rates of chronic illnesses necessitate more hospital beds and surgical interventions. The establishment of new hospitals and surgical facilities leads to a rise in the volume of operations performed, directly contributing to a higher probability of post-operative complications that require antiemetic solutions and management. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the United States possessed 6,129 hospitals, indicating a 0.591% increase from the 6,093 hospitals present in the previous year. Consequently, the growth in healthcare infrastructure is propelling the post-operative nausea and vomiting market.
What Segment Categories Shape The Post-Operative Nausea And Vomiting Market Segment Landscape?
The post-operative nausea and vomiting market covered in this report is segmented –
1) By Treatment Type: Serotonin Antagonists, Steroids, Dopamine Antagonists, Neurokinin NK-1 Receptor Antagonists, Non-pharmacological Treatment, Other Treatment Types
2) By Route Of Administration: Oral, Intravenous, Transdermal, Other Route Of Administrations
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Surgical Procedure Type: Orthopedic Surgery, Gynecological Surgery, General Surgery, Cardiac Surgery, Ophthalmic Surgery
5) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Serotonin Antagonists Type: Ondansetron, Granisetron, Palonosetron, Dolasetron, Tropisetron
2) By Steroids Type: Dexamethasone, Methylprednisolone, Hydrocortisone, Prednisolone, Betamethasone
3) By Dopamine Antagonists Type: Metoclopramide, Droperidol, Prochlorperazine, Domperidone, Chlorpromazine
4) By Neurokinin NK-1 Receptor Antagonists Type: Aprepitant, Fosaprepitant, Rolapitant, Netupitant, Casopitant
5) By Non-Pharmacological Treatment Type: Acupressure, Aromatherapy, Hypnotherapy, Electroacupuncture, Ginger Supplements
6) By Other Treatment Types: Antihistamines, Anticholinergics, Cannabinoids, Combination Therapy, Herbal & Natural Remedies
What Emerging Trends Are Seen In The Post-Operative Nausea And Vomiting Market?
Leading companies in the post-operative nausea and vomiting market are increasingly focused on creating vital injectable medications, exemplified by the introduction of regulatory-approved pharmaceutical injectables commercially to improve antiemetic treatments in medical environments. Such a launch indicates that an injectable drug, sanctioned by the FDA or other relevant authority, has been made available for clinical application after all requisite regulatory approvals and compliance steps are completed. As an illustration, in July 2024, Avenacy, a US-based specialty pharmaceutical firm, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials with the goal of assisting healthcare providers in minimizing dosing mistakes and enhancing patient safety. This particular injection is prescribed for the prevention of nausea and vomiting induced by chemotherapy and for the management of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery, thus presenting a dependable therapeutic choice for patients susceptible to these issues.
Who Are The Companies Operating Across The Post-Operative Nausea And Vomiting Market Value Chain?
Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited
Get The Full Post-Operative Nausea And Vomiting Market Report:
Which Region Is The Leading Market For The Post-Operative Nausea And Vomiting Market?
North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Post-Operative Nausea And Vomiting Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Post-Operative Nausea And Vomiting Market 2026, By The Business Research Company
Osteoporosis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report
Osteoporosis Drugs Market Report
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
Mineral And Bone Disorder Treatment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model